RxDoctor Payments Data

Angela Jones

Nurse Practitioner · Jonesboro, ARNPI 1790709038

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $76,464 of the $89,987 with a category attached, or 85.0%. Novo Nordisk accounts for 99.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $35,044 and has fallen 74.8% since, to $8,837 in 2025. Among nurse practitioner clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$89,987in general payments, 2019–2025

Across 183 payments — averaging $491.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$89K
  • AbbVie$254
  • GSK$119
  • Amgen$107
  • Stryker$102
  • Lilly USA, LLC$43
  • plus $162 from 8 others

What the payments were for

  • Speaking & faculty fees$76,46485%
  • Travel & lodging$9,78011%
  • Food & beverage$3,7434%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,987 in reported general payments places this provider in the 95th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$12,317
Medicare patients
44
Services billed
1,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$111,016
MounjaroTirzepatide14$16,432
JardianceEmpagliflozin13$9,669
LinzessLinaclotide18$9,640
TrintellixVortioxetine Hydrobromide14$7,141
Diclofenac Sodium25$703
Pantoprazole Sodium24$417
Omeprazole18$322
Montelukast Sodium11$198
Cyclobenzaprine Hcl21$175
Lisinopril13$172
Sertraline Hcl24$136
Topiramate39$125
Amlodipine Besylate20$117
Atorvastatin Calcium23$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$89,200$111,016109 claims
Lilly USA, LLCMounjaro$43$16,43214 claims
Boehringer IngelheimJardiance$21$9,66913 claims
AbbVieLinzess$254$9,64018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →